Month: July 2020

Recorded Webinar – Leveraging the Power of Interoperable eClinical Technology To Run Efficient Clinical Trials

07/21/2020

On July 15th TrialStat together with our partners Fujifilm TeraMedica and SimpleTrials held a joint webinar called Leveraging the Power of Interoperable eClinical Technology To Run Efficient Clinical Trials. We had a fantastic time producing and hosting this webinar taking advantage of some new video technology we developed to help produce a more exciting experience…

Read More

TrialStat Corporate Overview Video

07/21/2020

This year for DIA we produced a new corporate video which we shared through social media. At the time we did not get a chance to publish it here, and so I thought I’d take a few minutes and share it. You can watch the video below:

Read More

Centivax Antibody Effective in Reducing COVID-19 Lung Damage, Virus Levels and Symptoms as Both Therapeutic and Preventative in Healthy and Immunocompromised Hamsters; Confirmed by Multiple National Laboratories

07/21/2020

Excerpt from the press release: “SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Centivax Inc, the therapeutics spinout of Contract Research Organization Distributed Bio Inc, announced today that their antibody therapeutic protects hamsters from SARS-CoV-2, the COVID-19-causing coronavirus. Confirmed simultaneously at two independent national laboratories, these results provide critical support for the antibody to move to clinical studies to…

Read More

Ask Us Anything – Imaging In Clinical Trials

07/20/2020

We held our very first Virtual Networking event in this ongoing series we call Ask Us Anything In Clinical Research. We’ve all been missing out on in person networking events, and we wanted to do something about it. Each meeting is a casual event hosted once a month in the evening and is designed to…

Read More

‘Breakthrough’ treatment slashes coronavirus death risk: UK study

07/20/2020

Excerpt from the article: “An aerosol-based drug treatment could drastically reduce the number of new coronavirus patients dying from the disease or requiring intensive care, according to preliminary results released by a British biotech firm. In a randomised trial of 100 patients admitted to hospital with COVID-19, those who received an inhaled formula of the…

Read More

New Rapid Molecular Test For Tuberculosis Can Simultaneously Detect Resistance To First- And Second-Line Drugs

07/20/2020

Excerpt from the article: “GENEVA and SUNNYVALE, Calif., July 16, 2020 /PRNewswire/ — The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, announced today the launch of the new Xpert® MTB/XDR* test, which enables expanded drug-resistance tuberculosis (TB) profiling in less than 90 minutes. Xpert MTB/XDR can be used to empower clinicians to quickly prescribe…

Read More

PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

07/19/2020

Excerpt from the press release: MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–Jul. 16, 2020– PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046…

Read More

New Research Finds Asthma Drug Very Promising In Treating Alzheimer’s Disease

07/17/2020

Excerpt from the article: “A laboratory study determined that asthma drug salbutamol can help prevent the formation of proteins associated with Alzheimer’s disease. Since this was still a lab study, scientists wanted to take the next step of testing the drug in animal models. Brains of those suffering from Alzheimer’s disease show plaques between the…

Read More

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease

07/16/2020

Excerpt from the Press Release: “LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today reported clinical data demonstrating that its lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimer’s disease.…

Read More

Pear Therapeutics Announces First Participant Enrolled in Virtual Real-World Study of Adults with Chronic Insomnia

07/15/2020

Excerpt from the Press Release: “BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc. today announced the first participant enrolled in an open-label, decentralized clinical trial (called the DREAM study) evaluating Somryst™, an FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia. The DREAM study will enroll approximately 350 adults in the United States with…

Read More